The verdict
Our read at a glance.
Whether thymosin alpha-1/thymalfasin evidence supports any current, product-specific clinical claim outside narrow jurisdiction-specific or historical research contexts.
- The signal
- Human evidence is real but uneven. Historical chronic hepatitis studies, critical-illness and sepsis trials, severe pancreatitis research, COVID-era studies, vaccine-immunogenicity work, and oncology-adjunct studies each have different populations, endpoints, eras, and quality limits. The 2025 TESTS sepsis trial is an important boundary against treating sepsis mortality benefit as established.
- The unknown
- Which findings remain clinically relevant under current standards of care, whether any signal transfers across jurisdictions or product identities, and how to interpret compounding, immune, quality, and effectiveness concerns raised in FDA PCAC materials.
- Our read
- Source-rich, not simple. Thymosin alpha-1 belongs on the safety/regulatory watch because the literature is substantial, but the evidence is highly context-dependent and does not support broad immune-support, anti-aging, infection-prevention, cancer-treatment, or U.S.-approved-product claims.
The mechanism
How it works.
Thymosin alpha-1 is a 28-amino-acid peptide that the body cleaves from a larger thymic protein called prothymosin alpha. It acts on immune cells, partly by triggering Toll-like receptors that sense danger signals, and this pushes immature T cells to mature and tunes the activity of dendritic cells and natural-killer cells. Because it shifts broad immune signaling rather than hitting one target, it has been tested in infection, vaccine-response, critical-illness, and cancer-adjunct settings rather than for one defined disease.
Safety & regulatory boundary
The consequential part.
FDA PCAC materials are central to the U.S. compounding, product-identity, safety, and effectiveness boundary. Singapore Zadaxin records and FDA or EMA orphan-designation records are jurisdiction- or designation-specific and do not imply U.S. FDA approval. Thymosin alpha-1, thymalfasin, and Zadaxin should not be treated as equivalent to compounded products, research-use products, internet-market products, TB-500, thymosin beta-4, thymalin, thymulin, thymosin beta-10, or thymus extracts.
What's next
What we're watching.
FDA compounding decisions, registry-posted results, modern peer-reviewed trial publications, indication-specific safety reporting, product-identity documentation, and whether future reviews separate historical hepatitis, critical-care, COVID-era, vaccine-response, and oncology-adjunct evidence from broad immune or wellness claims.
Context
Why this is discussed.
Thymosin alpha-1 draws attention because Zadaxin/thymalfasin has regulated non-U.S. product records and decades of human literature, while internet narratives often collapse that record into broad immune-support, wellness, infection-prevention, or cancer-adjunct claims.
The evidence base
60 cited references.
Regulatory & labels9
FDA Global Substance Registration System · Current page checked 2026-05-16
Food and Drug Administration · 2024-12-04
Food and Drug Administration · 2024-12-04
Food and Drug Administration · 2024-12-04
Food and Drug Administration · 1998-01-08
Food and Drug Administration · 2006-03-13
European Medicines Agency · 2002-07-30; page updated 2003-01-08
Singapore National Drug Formulary · Last updated 2026-04-24
Singapore National Drug Formulary · Current page checked 2026-05-16
Peer-reviewed journals6
Liu F et al. · 2016
Wu J et al.; TESTS study collaborator group · 2025
Frontiers authors · 2025
Wang X, Wang Y, Chen X · 2023
Maio M et al. · 2010
Costantini C et al. · 2019
Indexed literature (PubMed)41
Ancell CD, Phipps J, Young L · 2001
Liaw YF · 2004
Chien RN, Liaw YF · 2004
Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS · 1998
Mutchnick MG et al. · 1991
Yang YF et al. · 2008
Zhang YY et al. · 2009
Peng J et al. · 2020
Wu X et al. · 2018
Amarapurkar DN, Das HS · 2002
Rasi G et al. · 1996
Andreone P et al. · 2004
Rustgi VK · 2004
Rustgi VK · 2005
Sherman KE · 2010
Wu J et al. · 2013
Li C et al. · 2015
Wang C et al. · 2016
Pei F, Guan X, Wu J · 2018
Ke L et al. · 2022
Tian X et al. · 2025
Liu Y et al. · 2020
Soeroto AY et al. · 2023
Shehadeh F et al. · 2023 / 2022 online
Tuthill C et al. · 2023
Gravenstein S et al. · 1989
Ershler WB, Gravenstein S, Geloo ZS · 2007
Panatto D et al. · 2011
Carraro G et al. · 2012
Cao H, Feng Y, Zhou X · 2024
Gish RG et al. · 2009
Niu Z et al. · 2024
Danielli R et al. · 2018
Garaci E et al. · 2003
Matteucci C et al. · 2017
Tuthill C, Rios I, McBeath R · 2010
Garaci E et al. · 2024
Dinetz I, Lee J · 2024
Pica F et al. · 2018
Stincardini C et al. · 2018
Camerini R, Garaci E · 2015
Sponsor & other sources4
National Cancer Institute · Current page checked 2026-05-16
PubChem · Current page checked 2026-05-16
Centre for Reviews and Dissemination · 2008
Sherman KE, Sherman SN · 1998
Keep reading